PFIZER - Pfizer Ltd. Share Price

Pharmaceuticals & Biotechnology

₹5067.50-47.50(-0.93%)

Market Closed as of Nov 6, 2025, 15:30 IST

Select time range

Valuation
Market Cap	23.4 kCr
Price/Earnings (Trailing)	28.93
Price/Sales (Trailing)	9.29
EV/EBITDA	20.47
Price/Free Cashflow	38.42
MarketCap/EBT	21.81
Enterprise Value	23.4 kCr

Fundamentals
Revenue (TTM)	2.52 kCr
Rev. Growth (Yr)	10.8%
Earnings (TTM)	808.64 Cr
Earnings Growth (Yr)	27.2%

Profitability
Operating Margin	36%
EBT Margin	43%
Return on Equity	19.17%
Return on Assets	16.47%
Free Cashflow Yield	2.6%

Price to Sales Ratio

Latest reported: 9

Revenue (Last 12 mths)

Latest reported: 3 kCr

Net Income (Last 12 mths)

Latest reported: 809 Cr

Growth & Returns
Price Change 1W	-3.3%
Price Change 1M	-2.1%
Price Change 6M	20%
Price Change 1Y	-1.4%
3Y Cumulative Return	4.3%
5Y Cumulative Return	0.70%
7Y Cumulative Return	8.5%
10Y Cumulative Return	7.6%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-71.34 Cr
Cash Flow from Operations (TTM)	659.75 Cr
Cash Flow from Financing (TTM)	-205.34 Cr
Cash & Equivalents	495.07 Cr
Free Cash Flow (TTM)	631.6 Cr
Free Cash Flow/Share (TTM)	138.06

Balance Sheet
Total Assets	4.91 kCr
Total Liabilities	693.7 Cr
Shareholder Equity	4.22 kCr
Current Assets	3.51 kCr
Current Liabilities	569.51 Cr
Net PPE	171.82 Cr
Inventory	475.92 Cr
Goodwill	527.49 Cr

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	111.36
Interest/Cashflow Ops	70.08

Dividend & Shareholder Returns
Dividend/Share (TTM)	200
Dividend Yield	3.91%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Pros

Size: Market Cap wise it is among the top 20% companies of india.

Dividend: Dividend paying stock. Dividend yield of 3.91%.

Balance Sheet: Strong Balance Sheet.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Profitability: Very strong Profitability. One year profit margin are 32%.

Smart Money: Smart money has been increasing their position in the stock.

Cons

Technicals: SharesGuru indicator is Bearish.

Momentum: Stock is suffering a negative price momentum. Stock is down -2.1% in last 30 days.

Past Returns: Underperforming stock! In past three years, the stock has provided 4.3% return compared to 13.5% by NIFTY 50.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	3.91%
Dividend/Share (TTM)	200
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	176.76

Financial Health
Current Ratio	6.17
Debt/Equity	0.00

Technical Indicators
RSI (14d)	24.62
RSI (5d)	13.41
RSI (21d)	44.92
MACD Signal	Sell
Stochastic Oscillator Signal	Buy
Grufity Signal	Sell
RSI Signal	Buy
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Summary of Latest Earnings Report from Pfizer

Summary of Pfizer's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Q&A Session

Last updated:

Share Holdings

Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
PFIZER EAST INDIA B V	39.75%
WYETH LLC	12.28%
NIPPON LIFE INDIA TRUSTEE LTD	4.17%
WYETH HOLDINGS CORPORATION	3.56%
WARNER-LAMBERT COMPANY LLC	2.6%
QUANT MUTUAL FUND	2.23%
ATUL LIMITED	2.1%
PARKE, DAVIS & COMPANY LLC	2.09%
JOHN WYETH & BROTHER LTD	1.93%
PHARMACIA CORPORATION	1.71%
SBI MUTUAL FUND	1.13%
ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTIC	1.03%
FOREIGN INSTITUTIONAL INVESTORS	0%
FOREIGN BANK	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Pfizer Better than it's peers?

Detailed comparison of Pfizer against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr

Sector Comparison: PFIZER vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

PFIZER metrics compared to Pharmaceuticals

Category	PFIZER	Pharmaceuticals
PE	28.93	35.96
PS	9.29	5.06
Growth	4.4 %	7.5 %

Performance Comparison

PFIZER vs Pharmaceuticals (2021 - 2025)

Key Insights

1. PFIZER is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.6% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Income Statement for Pfizer

Standalone figures (in Rs. Crores)

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	4%	2,281	2,193	2,425	2,611	2,239	2,152
Other Income	-5%	172	181	101	63	81	184
Total Income	3.4%	2,454	2,374	2,526	2,674	2,320	2,336
Cost of Materials	-19.1%	272	336	345	354	335	345
Purchases of stock-in-trade	9.4%	513	469	472	667	449	484
Employee Expense	6.6%	371	348	332	404	361	365
Finance costs	-47.1%	8.41	15	13	10	15	11
Depreciation and Amortization	-1.6%	61	62	106	115	109	103
Other expenses	-14.1%	359	418	411	424	368	422
Total Expenses	-1.6%	1,610	1,636	1,735	1,901	1,651	1,693
Profit Before exceptional items and Tax	14.2%	843	738	791	773	669	642
Exceptional items before tax	2374.8%	173	7.95	33	0	0	0
Total profit before tax	36.2%	1,016	746	824	773	669	642
Current tax	66.5%	264	159	252	218	184	133
Deferred tax	-147.5%	-15.61	36	-51.74	-58	-12.52	0.16
Total tax	27.3%	248	195	200	160	171	133
Total profit (loss) for period	39.5%	768	551	624	613	498	509
Other comp. income net of taxes	-105.8%	0.74	5.45	3.61	7.17	-0.96	-8.93
Total Comprehensive Income	37.9%	768	557	628	620	497	500
Earnings Per Share, Basic	39.6%	167.79	120.51	136.38	133.89	108.77	111.28
Earnings Per Share, Diluted	39.6%	167.79	120.51	136.38	133.89	108.77	111.28

Description	(%) Q/Q	Jun-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	12.1%	603	538	589	563	547	540
Other Income	57.1%	67	43	43	42	75	36
Total Income	15.3%	670	581	632	605	622	576
Cost of Materials	33.3%	89	67	77	58	89	77
Purchases of stock-in-trade	18.3%	124	105	81	188	94	149
Employee Expense	0%	96	96	101	91	75	89
Finance costs	341.2%	3.25	1.51	2.1	2.11	6.95	2.86
Depreciation and Amortization	-7.1%	14	15	15	15	14	18
Other expenses	-13.3%	86	99	88	93	93	115
Total Expenses	0.7%	411	408	416	402	378	408
Profit Before exceptional items and Tax	51.5%	260	172	215	203	244	168
Exceptional items before tax	-	0	0	0	0	0	7.95
Total profit before tax	51.5%	260	172	215	203	244	176
Current tax	34.7%	67	50	60	55	49	29
Deferred tax	90.3%	0.39	-5.26	-3.01	-3.14	16	17
Total tax	52.3%	68	45	57	52	65	46
Total profit (loss) for period	50.4%	192	128	158	151	179	130
Other comp. income net of taxes	-24.7%	-0.92	-0.54	-0.53	-0.54	7.93	-0.83
Total Comprehensive Income	50.8%	191	127	158	150	187	129
Earnings Per Share, Basic	52.1%	41.91	27.89	34.61	32.94	22.33	27.12
Earnings Per Share, Diluted	52.1%	41.91	27.89	0	32.94	22.33	27.12

Balance Sheet for Pfizer

Standalone figures (in Rs. Crores)

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	1352.9%	495	35	112	16	37	94
Loans, current	-	0	0	0	0	0	0.06
Total current financial assets	18.5%	2,998	2,531	2,247	2,082	2,076	1,781
Inventories	4.6%	476	455	434	399	418	457
Total current assets	16.2%	3,513	3,023	2,738	2,518	2,493	2,310
Property, plant and equipment	30.5%	172	132	151	164	178	199
Capital work-in-progress	264.8%	7.64	2.82	0.4	9.38	7.93	5.18
Investment property	-	0	0	0	0	0	27
Goodwill	0%	527	527	527	527	527	527
Loans, non-current	-	0	0	0	0	0	0.59
Total non-current financial assets	18.2%	14	12	14	13	13	19
Total non-current assets	-0.4%	1,398	1,404	1,459	1,457	1,476	1,486
Total assets	10.1%	4,911	4,459	4,229	4,006	4,001	3,831
Total non-current financial liabilities	81.1%	68	38	0	73	93	150
Provisions, non-current	-12.5%	57	65	0	46	43	0
Total non-current liabilities	20.6%	124	103	87	119	136	150
Borrowings, current	0%	2.5	2.5	2.5	2.5	2.5	2.5
Total current financial liabilities	-17.5%	232	281	206	323	322	292
Provisions, current	-10.7%	51	57	45	93	101	76
Current tax liabilities	21.5%	221	182	160	164	161	188
Total current liabilities	-5.8%	570	605	547	614	657	764
Total liabilities	-2%	694	708	633	733	793	914
Equity share capital	0%	46	46	46	46	46	46
Total equity	12.4%	4,217	3,751	3,596	3,273	3,207	2,916
Total equity and liabilities	10.1%	4,911	4,459	4,229	4,006	4,001	3,831

Cash Flow for Pfizer

Standalone figures (in Rs. Crores)

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-47.1%	8.41	15	0	10	-	-
Change in inventories	-154.2%	-42.22	-16	22	-13.86	-	-
Depreciation	-1.6%	61	62	106	115	-	-
Unrealised forex losses/gains	40.2%	0.21	-0.32	0	0	-	-
Adjustments for interest income	-100.6%	0	172	85	49	-	-
Share-based payments	0%	14	14	13	12	-	-
Net Cashflows from Operations	137.1%	973	411	854	893	-	-
Interest received	-	-157.27	0	0	0	-	-
Income taxes paid (refund)	1.3%	156	154	303	226	-	-
Other inflows (outflows) of cash	-	0	0	-195.31	0	-	-
Net Cashflows From Operating Activities	157.4%	660	257	356	667	-	-
Proceeds from sales of PPE	18.4%	0.2	0.02	1.22	2.06	-	-
Purchase of property, plant and equipment	50%	28	19	65	15	-	-
Proceeds from sales of long-term assets	190.4%	152	53	0	0	-	-
Interest received	7.8%	139	129	71	44	-	-
Other inflows (outflows) of cash	-204.7%	-334.43	-109.1	-43.4	-605.54	-	-
Net Cashflows From Investing Activities	-236.5%	-71.34	54	-36.05	-575.02	-	-
Payments of lease liabilities	10%	45	41	35	0	-	-
Dividends paid	-12.6%	160	183	297	160	-	-
Interest paid	-107%	0.3	11	13	0.78	-	-
Other inflows (outflows) of cash	-	0	0	-0.63	-19.99	-	-
Net Cashflows from Financing Activities	12.6%	-205.34	-235.14	-345.79	-180.51	-	-
Net change in cash and cash eq.	416.2%	383	75	-26.14	-88.45	-	-

What does Pfizer Ltd. do?

Pharmaceuticals•Healthcare•Small Cap

Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:1,721

Website:www.pfizerltd.co.in

PFIZER - Pfizer Ltd. Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Pfizer Ltd. do?